GP-Act III Acquisition Overview
Valuation check: GPAT's ROE is -51.8%, below the sector sector average of -5.84%.
Get informed when a big investor buys or sells
+ Follow-51.80%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for GPAT is -51.8%. That is below the sector sector average of -5.84%. Investors often review this figure alongside GP-Act III Acquisition's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, GPAT currently prints -51.8% for ROE, while the sector average sits near -5.84%. That is roughly 786.3% below the sector mean. Large gaps often invite a closer look at GP-Act III Acquisition's growth, margins, and balance sheet.
Return on Equity shows how effectively GP-Act III Acquisition converts resources into returns. At -51.8%, GPAT may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting GPAT's ROE (-51.8%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
